June 2015 Edition Vol.11, Issue 6

Cancer Immunotherapy at ASCO: Bringing Down the House

Cancer Immunotherapy at ASCO:
Bringing Down the House

By Neil Canavan

Cancer immunotherapy took over the spotlight at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). For proof, look no further than the abstracts chosen for the opening session—all three focused on the immunotherapy (IO) drug class known as, Checkpoint Inhibitors.  

Dr. Neil Segal, Memorial Sloan Kettering Cancer Center, opened the session by giving a brief micro- to macro-view of the immunotherapy field.  

“In 2010, the first Phase 3 clinical trial with an immune checkpoint inhibitor, anti CTLA-4, ipilimumab, was reported. This study showed a survival benefit in advanced melanoma with a survival of 10.1 months for ipilimumab (plus the Gp100 melanoma vaccine) vs 6.4 months for gp100 alone.” This result was a revelation, and caught the attention of oncology researchers all over the world.

From that single trial sprung many. Of the 6,018 investigational studies now listed on Clinicaltrials.gov, 279 of them have an IO component. As Dr. Segal pointed out, “That’s one of every 22.”

Day One, for Openers: PD-1

Kicking off the meeting, and presented before a packed room were the interim results of a Phase 1/2 study looking at the use of the PD-1 (checkpoint) inhibitor, nivolumab, in a cohort of patients with advanced hepatocellular carcinoma.

“This disease is the second most frequent cause of cancer death,” said study investigator, Anthony El-Khoueiry, MD, University of Southern California Norris Comprehensive Cancer Center, Los Angeles. Sorafenib, a kinase inhibitor, is the standard of care in this setting, with median survival rates of 7 to 8 months. “There is no standard of care after failure on sorafenib.”

Dr. El-Khoueiry explained the rationale for using IO in this setting. “Typically, this is an inflammation-associated cancer and is immunogenic,” and therefore, has lots of T cells already in the vicinity of the tumor — T cells that are primed to have their activity unleashed by a checkpoint inhibitor. In a healthy individual the checkpoints block excess T cell activity in order to prevent autoimmune disorders.

As far as using nivolumab, which blocks the PD-1 receptor, it was previously shown that hepatitis infection is associated with an up-regulation of PD-1 expression.

This dose-ranging study enrolled HCV, HBV, as well as uninfected patients (N=200).

Results showed that, overall, 19% of patients experienced objective responses. “Two had complete responses, and 48% had stable disease,” said Dr. El-Khoueiry. Further, durable responses were observed across all dose levels and etiologic cohorts.

For survival, “Given the fact that many patients are still on study therapy, the overall survival (OS) data are preliminary.” That said, at 9 months the survival rate was 70%, and at one year the rate of survival was 62%. “To put this in context, the 12 month survival rate after sorafenib failure is about 30%,“ said Dr. El-Khoueiry.

Commenting on the results, Lawrence Fong, MD, UCSF, was optimistic. “Hepatocellular carcinoma represents another difficult-to-treat cancer where PD-1 axis targeting appears to have clinical activity, and with modest toxicity,” he said. “I think this really highlights an exciting development for patients with this challenging disease.”


Putting yet another feather in the nivolumab cap, Luis Paz-Ares, MD, PhD, Hospital Universitario Doce de Octubre, Madrid, presented results for the CheckMate 057 trial, an investigation comparing the use of nivolumab versus docetaxel in a cohort of patients with advanced, non-squamous, non-small cell lung cancer (NS-NSCLC; N=582) (Figure 1).

“These patients, after progression on platinum-based doublets, have few options,” said Dr. Paz-Ares. “The median overall survival is from 8 to 10 months.”

The rationale for using a PD-1 inhibitor in this patient setting is the activity observed with nivolumab in NSCLC patients with the squamous histology.

Results showed an overall response rate of 19% for the checkpoint inhibitor arm vs 9.4% for standard-of-care docetaxel arm (Figure 2). The median overall survival was 12.2 months for nivolumab vs 9.4 months for docetaxel (P=0.001). “With a hazard ratio of 0.73, this translates into a reduction of death otherwise expected of roughly 27%,” said Dr. Paz-Ares.

Increasing survival with nivolumab was observed to correlate with levels of PD-L1 expression; there was no improvement in survival reported for any PD-1 negative patients.

The discussant for this study, Roy Herbst, MD, PhD, Yale School of Medicine, said, “About 20 years ago some of us sat in a meeting in Los Angeles and we heard about Phase 1 studies of carboplatin and paclitaxel, and the wonderful response rates in lung cancer—look how far we’ve come.”

Nivolumab was recently FDA-approved for squamous cell NSCLC in March.

To be clear: “Is this the new standard of care for the treatment of previously treated, non-squamous non-small cell lung cancer?” asked Dr. Herbst. “Yes. This is a positive randomized Phase 2 trial that met its primary endpoint for all comers. This sets a new standard for previously treated disease, and now we need to move this to front-line therapy for the appropriate patients.”

Pages: 1 2

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.